openPR Logo
Press release

Gastrointestinal Stromal Tumor (GIST) Pipeline Analysis, 2017 - Clinical Trials & Results, Patent and Other Developments

05-23-2017 12:08 AM CET | Health & Medicine

Press release from: P&S Market Research - Pharmaceuticals

Gastrointestinal Stromal Tumor (GIST) Pipeline Analysis, 2017

The gastrointestinal stromal tumor (GIST) pipeline will rise with various collaborations and R&D investments. Hereditary risk and genetic factors play an important role in the development of gastrointestinal stromal tumor. Increasing family history of the disease and genetic factors associated with gastrointestinal stromal tumor and low penetration in the market are contributing towards the development of the pipeline. Additionally, increasing awareness regarding various health issues among people is another major factor fueling the pipeline growth for gastrointestinal stromal tumor. According to American Cancer Society, every year around 4,000 to 5,000 people suffer from gastrointestinal stromal tumor in the U.S. Gastrointestinal stromal tumors occur mostly in older adults with age more than 50 years. It affects women and men equally.

Explore Report at: www.psmarketresearch.com/market-analysis/gastrointestinal-stromal-tumor-pipeline-analysis

Gastrointestinal stromal tumorsis rare form of tumor which is found in gastrointestinal tract or digestive tract. It mostly occurs on the walls of stomach, varying from benign to malignant. The symptoms of gastrointestinal stromal tumors include pain or discomfort in the stomach, blood in vomit or stools, fatigue, sickness and anaemia. But in the early stages of the disease symptoms does not occur resulting in late diagnosis of the tumor. The diagnosis of Gastrointestinal stromal tumors is done by conducting endoscopy, magnetic resonance imaging (MRI) and computed tomography (CT) scan. The treatment of gastrointestinal stromal tumors include surgery and biological therapies. Surgery is the most common treatment for gastrointestinal stromal tumors and it is chosen by analysing the location of the tumor and the size of the tumor. Biological therapies include treatment with drugs including Imatinib (Glivec), Sunitinib (Sutent) and Regorafenib (Stivarga).

Request for Table of Content at: www.psmarketresearch.com/market-analysis/gastrointestinal-stromal-tumor-pipeline-analysis/toc-sample

Some of the companies having a pipeline of gastrointestinal stromal tumors therapeutics include Chipscreen Biosciences Ltd., GlaxoSmithKline plc, Pfizer, Boston Biomedical, Inc., Bayer AG, Immunicum AB, Plexxikon, Inc., Blueprint Medicines Corporation, Array BioPharma Inc., ArQule, Inc., Arog Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Deciphera Pharmaceuticals LLC.

Browse Other Related Report at: www.psmarketresearch.com/industry-report/pharmaceuticals

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
Kundan
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Gastrointestinal Stromal Tumor (GIST) Pipeline Analysis, 2017 - Clinical Trials & Results, Patent and Other Developments here

News-ID: 546490 • Views: 351

More Releases from P&S Market Research - Pharmaceuticals

Psoriasis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Paten …
The study analyzed that the psoriasis therapeutics pipeline comprises approximately 150 drug candidates in different stages of development. Psoriasis is a chronic inflammatory disorder that causes red patches covered with white scales on the skin. It is characterized when a person’s immune system sends defective signals which results in skin cells to grow rapidly. The body does not shed these excess skin cells and pile up on the surface of
Diabetic Foot Ulcer Therapeutics Pipeline Projects Immense Growth Ahead
The study analysed that the diabetic foot ulcer pipeline comprises of approximately 27 drug candidates in different stages of development. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/diabetic-foot-ulcers-therapeutics-pipeline-analysis Diabetic foot ulcer is a serious complication of diabetes and can be defined as the ulceration in foot along with neuropathy or peripheral artery disease of the lower limb in diabetic patients. Diabetic foot ulcer is categorized into two types namely; neuropathic foot where
Technological Advancements at Cellular and Molecular Level Strengthening the IgA …
The pipeline involves drug candidates that are being developed using specific targets such as a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BlyS). More than three drug candidates are being developed using subcutaneous route of administration. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/iga-nephropathy-pipeline-analysis The study analyzed that the IgA nephropathy therapeutics pipeline comprises of 24 drug candidates in different stages of development. The report also includes epidemiology forecast for IgA Nephropathy for the
Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Pipeline Analysis, 2017
The study analyzed that the IPF pipeline comprised of 104 drug candidates, of which 19 drugs are in the Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. There are various drugs that are being developed as novel and promising therapeutics for the treatment of IPF. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeutics-market As per the findings of research, it

All 5 Releases


More Releases for Gastrointestinal

Gastrointestinal Devices Market – Latest Advancements
Gastrointestinal Devices Market report 2018-2026 focuses on the major drivers and restraints for the key players. These research report also provides granular analysis of the market share, segmentation, revenue forecasts and geographic regions of the market. The Gastrointestinal Devices market research report is a professional and in-depth study on the current state of Gastrointestinal Devices Industry. The Gastrointestinal Devices Market research report covers the present scenario and the growth prospects
Gastrointestinal Devices Market Report 2018: Segmentation by Type (Gastrointesti …
Global Gastrointestinal Devices market research report provides company profile for Coloplast, Given Imaging, CONMED, Covidien, Ethicon, Olympus, Boston Scientific and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to 2025, etc. The report also provides detailed segmentation
Gastrointestinal Drugs Market - Upcoming Trends
The global gastrointestinal drugs market is consolidated with the top three players accounting for a whopping 61% of the market collectively in 2016. These three players are: Valeant Pharmaceuticals Inc., Janssen Biotech Inc., and Takeda Pharmaceutical. While the market is moderately competitive at present, future holds much competitiveness among players and thus, the degree of competition is expected to be increase in the forecast period, states a report by Transparency
Global Gastrointestinal Drugs Sales Market Report 2017
In this report, the global Gastrointestinal Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. The Values marked with XX is confidential data. To know more about CAGR figures fill in your information so that our business development executive can get in touch with you. Request Sample Copy
Recent Advances in Gastrointestinal Stents Industry Development
Global Gastrointestinal Stents Market: Snapshot The global gastrointestinal stents market displays competition despite strong foothold of a few dominant players. To outdo the competition, mergers and acquisitions to enhance technical expertise is what players are vying for in this market. Development of differentiator products is also what players are looking upon to stay ahead in the game. Among the key factors catalyzing growth of the global gastrointestinal stents market are
Global Gastrointestinal Industry Report 2016
Global Gastrointestinal Industry 2016 Market Overview, Size, Share, Trends, Analysis, Technology, Applications, Growth, Market Status, Demands, Insights, Development, Research and Forecast 2016-2020. The analysts of the global Gastrointestinal market report have taken on the challenge of procuring insightful data from reliable resources and precisely segregating critical market dynamics, given the voluminous amount of information available. Established and novice players in the Gastrointestinal market can secure their position on the cutting edge